Product Name: Pim1-III
Product Number: AB-NK258-1
| Size: | 25 µg | Price: | 89.00 | |
| $US |
Target Full Name: Proto-oncogene serine/threonine-protein kinase Pim-1
Target Alias: Pim; ENSG00000137193
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK258-1
Antibody Target Type: Pan-specific
Protein UniProt: P11309
Protein SigNET: P11309
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human Pim1 sequence peptide Cat. No.: PE-01AQM80
Antibody Immunogen Sequence: VEKDRISDWGELPNGTRVPMEVGGC
Target Alias: Pim; ENSG00000137193
Product Type Specific: Protein kinase pan-specific antibody
Antibody Code: NK258-1
Antibody Target Type: Pan-specific
Protein UniProt: P11309
Protein SigNET: P11309
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human Pim1 sequence peptide Cat. No.: PE-01AQM80
Antibody Immunogen Sequence: VEKDRISDWGELPNGTRVPMEVGGC
Antibody Immunogen Description: Corresponds to amino acid residues V160 to V181; Kinase catalytic subdomain 3
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Production Method: The immunizing peptide was produced by solid phase synthesis on a multipep peptide synthesizer and purified by reverse-phase hplc chromatography. Purity was assessed by analytical hplc and the amino acid sequence confirmed by mass spectrometry analysis. This peptide was coupled to KLH prior to immunization into rabbits. New Zealand White rabbits were subcutaneously injected with KLH-coupled immunizing peptide every 4 weeks for 4 months. The sera from these animals was applied onto an agarose column to which the immunogen peptide was thio-linked. Antibody was eluted from the column with 0.1 M glycine, pH 2.5. Subsequently, the antibody solution was neutralized to pH 7.0 with saturated Tris.
Antibody Modification: Unconjugated. Contact KInexus if you are interest in having the antibody biotinylated or coupled with fluorescent dyes.
Antibody Concentration: 0.14 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Strong detection of ~45 kDa target-sized protein in mouse brain and 37 kDa protein in mouse skeletal muscle.
Antibody Species Reactivity: Human
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Strong detection of ~45 kDa target-sized protein in mouse brain and 37 kDa protein in mouse skeletal muscle.
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 37-45 kDa.
Antibody Specificity: High
Antibody Cross Reactivity: Very strong cross-reactive ~72 kDa protein in A431 and HEK-293 cells.
Related Product 1: Pim1-III blocking peptide
Related Product 2: Pim1-BKCD pan-specific antibody (Cat. No.: AB-NK258-2)
Related Product 3: PimSelectide - Pim1 protein kinase substrate peptide
Related Product 4: RPS6 (230-238) KinSub - 40S ribosomal protein S6 (K230-R238, human) peptide; p70S6K protein kinase substrate peptide
Antibody Specificity: High
Antibody Cross Reactivity: Very strong cross-reactive ~72 kDa protein in A431 and HEK-293 cells.
Related Product 1: Pim1-III blocking peptide
Related Product 2: Pim1-BKCD pan-specific antibody (Cat. No.: AB-NK258-2)
Related Product 3: PimSelectide - Pim1 protein kinase substrate peptide
Related Product 4: RPS6 (230-238) KinSub - 40S ribosomal protein S6 (K230-R238, human) peptide; p70S6K protein kinase substrate peptide
Scientific Background: Pim1 is a protein-serine/threonine kinase of the CAMK group and Pim family. The expression of Pim1 in normal tissues is almost undetectable, but it is widely distributed in most tested human tissues. Its expression can be stimulated by a variety of growth factors and is regulated at four different levels: transcriptional, post-transcriptional, translational and post-translational. Expression of Pim1 is mediated through activation of the JAK/STAT pathway. Pim1 is activated by phosphorylation at S280 and Y309 (by Etk). Pim1 is involved in the control of cytokine-mediated cell proliferation, differentiation and survival of lymphoid and myeloid cells as well as others. Pim1 was originally identified as a transduced oncogene from Moloney murine leukemia virus induced T-cell lymphomas in mice. The Pim1 protein is undergoes relatively little mutation in human tumours, about the same as typical proteins. The oncogenic activity of the Pim-1 protein is mediated through the positive regulation of Myc transcription, the regulation of cell cycle progression, and by the inhibition of the pro-apoptotic proteins BAD, MAP3K5, and FOXO3. In addition, Pim-1 has been shown to promote genomic instability. Gain-of-function mutations in the Pim-1 gene resulting in the up-regulation of Pim-1 activity have been observed in several human cancer types, indicating a role in tumourigenesis. For example, significantly elevated Pim-1 expression was observed in several hematopoietic malignancies and in several solid tumours. In animal studies, over-expression of the Pim-1 protein in mice leads to an increased occurence of tumours, while the knockout of Pim-1 expression has no observable phenotypic consequence. Pim1 has been linked with the development of prostate cancer, colorectal adenocarcinomas, large-cell lymphomas and hematopoietic malignancies.
© Kinexus Bioinformatics Corporation 2017